Cellectar receives orphan drug designation from the european commission for clr 131 in waldenstrom's macroglobulinemia

Benefits include 10 years of market exclusivity in the european union benefits include 10 years of market exclusivity in the european union

CLRB Ratings Summary

CLRB Quant Ranking